ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, co-treatment with martinostat and imatinib further reduced BCR-ABL and STAT5 expression in both imatinib-sensitive and imatinib-resistant K562 cells, suggesting that martinostat is a potential therapeutic candidate for CML, either alone or with TKIs.